Effects of disruption of the nucleotide pattern in CRID element and Kozak sequence of interferon β on mRNA stability and protein production

References

• Peters, M. 1996. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology 23: 909–916
   PubMed Web of Science ®Google Scholar
• Uzé, G., G. Lutfalla, and K. E. Mogensen. 1995. Alpha and beta interferons and their receptor and their friends and relations. J. Interferon Cytokine Res. 15: 3–26
   PubMed Web of Science ®Google Scholar
• Bekisz, J., H. Schmeisser, J. Hernandez, et al. 2004. Mini review human interferons alpha, beta and omega. Growth Factors 22: 243–251
   PubMed Web of Science ®Google Scholar
• de Veer, M. J., M. Holko, M. Frevel, et al. 2001. Functional classification of interferon-stimulated genes identified using microarrays. J. Leukoc. Biol. 69: 912–920
   PubMed Web of Science ®Google Scholar
• Garbe, C., K. Krasagakis, C. C. Zouboulis, et al. 1990. Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J. Invest. Dermatol. 95: 231S–237S
   PubMed Web of Science ®Google Scholar
• Hong, J., M. V. Tejada-Simon, V. M. Rivera, et al. 2002. Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult. Scler. 8: 237–242
   PubMed Web of Science ®Google Scholar
• Pang, K. R., J. J. Wu, D. B. Huang, et al. 2005. Biological and clinical basis for molecular studies of interferons. Methods Mol. Med. 116: 1–23
   PubMedGoogle Scholar
• Dhib-Jalbut, S., and S. Marks. 2010. Interferon- β mechanisms of action in multiple sclerosis. Neurology 74: S17–S24
   PubMed Web of Science ®Google Scholar
• Javed, A., and A. T. Reder. 2006. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol. Ther. 110: 35–56
   PubMed Web of Science ®Google Scholar
• Kay, M., Z. Hojati, and F. Dehghanian. 2013. The molecular study of IFNβ pleiotropic roles in MS treatment. Iran J. Neurol. 12: 149–156
   PubMedGoogle Scholar
• Cirelli, R., and S. K. Tyring. 1995. Major therapeutic uses of interferons. Clin. Immunother. 3: 27–87
   Google Scholar
• Jacobs, L. D., Cookfair, D. L., Rudick, R. A., et al. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39: 285–294
   PubMed Web of Science ®Google Scholar
• Arababadi, M. K., R. Mosavi, H. Khorramdelazad, et al. 2010. Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex in relapsing remitting multiple sclerosis in Iranian patients. Biomark Med. 4: 755–759
   PubMed Web of Science ®Google Scholar
• Itoh, S., T. Nishi, T. Mizukami, et al. 1987. Recombinant plasmid containing human interferon-beta gene. EP Patent 0,083,069
   Google Scholar
• McCormick, F. P., M. A. Innis, and G. M. Ringold. 1998. Human interferon-beta (IFN-beta) produced in Chinese hamster ovary (CHO) cells. US Patent 5,795,779
   Google Scholar
• Khabar, K. S. A., and H. A. Young. 2007. Post-transcriptional control of the interferon system. Biochimie 89: 761–769
   PubMed Web of Science ®Google Scholar
• Paste, M., G. Huez, and Vr. Kruys. 2003. Deadenylation of interferon β mRNA is mediated by both the AU rich element in the 3′untranslated region and an instability sequence in the coding region. Eur. J. Biochem. 270: 1590–1597
   PubMedGoogle Scholar
• Raj, N. B., and P. M. Pitha. 1993. 65-kDa protein binds to destabilizing sequences in the IFN-beta mRNA coding and 3′UTR. FASEB J. 7: 702–710
   PubMed Web of Science ®Google Scholar
• Kozak, M. 1991. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J. Biol. Chem. 266: 19867–19870
   PubMed Web of Science ®Google Scholar
• Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402–408
   PubMed Web of Science ®Google Scholar
• Whittemore, L. A., and T. Maniatis. 1990. Postinduction turnoff of beta-interferon gene expression. Mol. Cell Biol. 10: 1329–1337
   PubMed Web of Science ®Google Scholar
• Johnson-Jackson, D., K. Furuya, I. Zaror, and D. Larson. 2007. Recombinant interferon beta with enhanced biological activity. WO Patent App. PCT/US2007/016,722
   Google Scholar
• Pepinsky, R. B., D. J. Lepage, A. Gill, et al. 2001. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-b-1a with preserved in vitro bioactivity. J. Pharmacol. Exp. Ther. 297: 1059–1066
   PubMed Web of Science ®Google Scholar
• So, M. K., J.-M. Lee, J.-H. Yang, et al. 2006. Human interferon beta mutein. WO Patent App. PCT/KR2005/003,665
   Google Scholar
• Otto, B., C. Schneider-Fresenius, and G. Waschutza. 2009. Human recombinant beta-interferon with improved solubility. US Patent 6,572,853
   Google Scholar
• Carr, F., G. Carter, T. Jones, et al. 2002. Modified interferon beta with reduced immunogenicity. WO Patent App. PCT/EP2002/002,925
   Google Scholar